{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:22:23Z","timestamp":1771078943698,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Amyloidosis is a systemic disorder characterized by extracellular deposition of insoluble fibrils. The most common forms are amyloid light chain and amyloid transthyretin (ATTR) amyloidoses. Cardiac involvement may be found in both these forms, and is an important cause of morbidity and mortality. The clinical presentation of cardiac amyloidosis (CA) may be represented by congestive heart failure (HF), possibly progressing to end-stage HF, as well as atrial fibrillation with possible thromboembolic events, and also conduction disturbances related to amyloid infiltration of conduction fibres. Beyond therapies targeting the blood dyscrasia or the ATTR amyloidogenic cascade, a careful choice of drug therapies, need for device implantation, and possibly treatments for advanced HF is then warranted. In the present review, we try to provide a useful guide to clinicians treating patients with CA by enucleating 10 main questions and answering them based on the evidence available as well as expert opinion and our clinical experience.<\/jats:p>","DOI":"10.1177\/2047487320920756","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T02:07:36Z","timestamp":1587089256000},"page":"1000-1005","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Management of complications of cardiac amyloidosis: 10 questions and answers"],"prefix":"10.1093","volume":"28","author":[{"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Rapezzi","sequence":"additional","affiliation":[{"name":"University of Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Italy"},{"name":"Fondazione Toscana Gabriele Monasterio, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Giannoni","sequence":"additional","affiliation":[{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Italy"},{"name":"Fondazione Toscana Gabriele Monasterio, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Spini","sequence":"additional","affiliation":[{"name":"Fondazione Toscana Gabriele Monasterio, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Passino","sequence":"additional","affiliation":[{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Italy"},{"name":"Fondazione Toscana Gabriele Monasterio, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Italy"},{"name":"Fondazione Toscana Gabriele Monasterio, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"2021121221184845300_zwaa336-B1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000444206","article-title":"The prevalence and management of systemic amyloidosis in western countries","volume":"2","author":"Nienhuis","year":"2016","journal-title":"Kidney Dis (Basel)"},{"key":"2021121221184845300_zwaa336-B2","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","author":"Vergaro","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2021121221184845300_zwaa336-B3","article-title":"Red flags in cardiac amyloidosis","author":"Kwok","year":"24","journal-title":"Eur J Prev Cardiol"},{"key":"2021121221184845300_zwaa336-B4","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2021121221184845300_zwaa336-B5","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"2021121221184845300_zwaa336-B6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.05.018","article-title":"Therapies for cardiac light chain amyloidosis: an update","volume":"271","author":"Aimo","year":"2018","journal-title":"Int J Cardiol"},{"key":"2021121221184845300_zwaa336-B7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2021121221184845300_zwaa336-B8","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"2021121221184845300_zwaa336-B9","doi-asserted-by":"crossref","first-page":"e006588","DOI":"10.1161\/CIRCIMAGING.117.006588","article-title":"Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis","volume":"11","author":"Milani","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"2021121221184845300_zwaa336-B10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021121221184845300_zwaa336-B11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart"},{"key":"2021121221184845300_zwaa336-B12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.acvd.2018.03.004","article-title":"Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure","volume":"111","author":"d\u2019Humieres","year":"2018","journal-title":"Arch Cardiovasc Dis"},{"key":"2021121221184845300_zwaa336-B13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"key":"2021121221184845300_zwaa336-B14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"2021121221184845300_zwaa336-B15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2021121221184845300_zwaa336-B16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.healun.2013.01.987","article-title":"Left ventricular device implantation for advanced cardiac amyloidosis","volume":"32","author":"Swiecicki","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"2021121221184845300_zwaa336-B17"},{"key":"2021121221184845300_zwaa336-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2021121221184845300_zwaa336-B19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.healun.2011.09.010","article-title":"Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies","volume":"31","author":"Varr","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"2021121221184845300_zwaa336-B20","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"2021121221184845300_zwaa336-B21","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021121221184845300_zwaa336-B22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jbspin.2006.12.006","article-title":"Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis","volume":"74","author":"Sellam","year":"2007","journal-title":"Joint Bone Spine"},{"key":"2021121221184845300_zwaa336-B23","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF","volume":"67","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021121221184845300_zwaa336-B24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021121221184845300_zwaa336-B25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/0003-4819-55-6-989","article-title":"Cardiac amyloidosis. Two cases with digitalis sensitivity","volume":"55","author":"Cassidy","year":"1961","journal-title":"Ann Intern Med"},{"key":"2021121221184845300_zwaa336-B26","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"key":"2021121221184845300_zwaa336-B27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"key":"2021121221184845300_zwaa336-B28","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2021121221184845300_zwaa336-B29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10840-019-00517-y","article-title":"Pacemaker implantation in familial amyloid polyneuropathy: when and for whom?","volume":"55","author":"Milner","year":"2019","journal-title":"J Interv Card Electrophysiol"},{"key":"2021121221184845300_zwaa336-B30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Heart Rhythm"},{"key":"2021121221184845300_zwaa336-B31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10286-019-00623-x","article-title":"Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management","volume":"29","author":"Palma","year":"2019","journal-title":"Clin Auton Res"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2047487320920756","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2047487320920756","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/9\/1000\/41728619\/zwaa336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/9\/1000\/41728619\/zwaa336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T21:19:02Z","timestamp":1639343942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/28\/9\/1000\/6353467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,4,16]]},"published-print":{"date-parts":[[2021,8,9]]}},"URL":"https:\/\/doi.org\/10.1177\/2047487320920756","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2020,4,16]]}}}